130 related articles for article (PubMed ID: 32305182)
1. Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
Qin M; Tian Y; Han X; Cao Q; Zheng S; Liu C; Wu X; Liu L; Meng Y; Wang X; Zhang H; Hou Y
Bioorg Med Chem; 2020 Jun; 28(11):115486. PubMed ID: 32305182
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
3. Targeting tyrosine kinase: Development of acridone - pyrrole - oxindole hybrids against human breast cancer.
Kaur M; Singh P
Bioorg Med Chem Lett; 2019 Jan; 29(1):32-35. PubMed ID: 30446310
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation and molecular docking of new sulfonamide-based indolinone derivatives as multitargeted kinase inhibitors against leukemia.
El-Hussieny M; El-Sayed NF; Fouad MA; Ewies EF
Bioorg Chem; 2021 Dec; 117():105421. PubMed ID: 34666258
[TBL] [Abstract][Full Text] [Related]
7. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.
Im D; Jung K; Yang S; Aman W; Hah JM
Eur J Med Chem; 2015 Sep; 102():600-10. PubMed ID: 26318067
[TBL] [Abstract][Full Text] [Related]
9. Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
Qin M; Yan S; Wang L; Zhang H; Tian Y; Zhao Y; Gong P
Bioorg Med Chem; 2017 Mar; 25(6):1778-1786. PubMed ID: 28190652
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of substituted biphenyl methylene indolinones as apoptosis inducers and tubulin polymerization inhibitors.
Donthiboina K; Anchi P; Sri Ramya PV; Karri S; Srinivasulu G; Godugu C; Shankaraiah N; Kamal A
Bioorg Chem; 2019 May; 86():210-223. PubMed ID: 30716619
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
[TBL] [Abstract][Full Text] [Related]
12. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
[TBL] [Abstract][Full Text] [Related]
13. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides.
Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE
Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer.
Wei W; Feng Z; Liu Z; Li X; He H; Ran K; Shi Y; Zhu Y; Ye T; Gao C; Wang N; Yu L
Eur J Med Chem; 2022 Jan; 228():113978. PubMed ID: 34810020
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
[TBL] [Abstract][Full Text] [Related]
16. Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile.
Sestito S; Bacci A; Chiarugi S; Runfola M; Gado F; Margheritis E; Gul S; Riveiro ME; Vazquez R; Huguet S; Manera C; Rezai K; Garau G; Rapposelli S
Eur J Med Chem; 2021 Dec; 226():113895. PubMed ID: 34624821
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate.
Chen T; Zhuo LS; Liu PF; Fang WR; Li YM; Huang W
Eur J Med Chem; 2020 Apr; 192():112174. PubMed ID: 32113049
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 4-aryl-thieno[1,4]diazepin-2-one derivatives targeting multiple protein kinases as anticancer agents.
Lee J; Jung H; Kim M; Lee E; Im D; Aman W; Hah JM
Bioorg Med Chem; 2018 May; 26(8):1628-1637. PubMed ID: 29459144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
